GLP-1 therapies have rapidly changed the landscape of metabolic medicine.
Originally established as a treatment approach for type 2 diabetes, GLP-1 receptor agonists are now at the center of major clinical development programs across obesity and a growing range of related metabolic conditions.
Recent developments demonstrate just how quickly the field is evolving. Semaglutide is now approved in the US not only for chronic weight management, but also for metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis, highlighting the expanding potential of GLP-1 therapies beyond diabetes and obesity.
For sponsors, this creates significant opportunity. But as development activity increases, so does competition for patients, sites and resources.
Large potential patient populations do not automatically make clinical trials easier to deliver. Increasingly, the ability to make participation practical, accessible and sustainable for patients can be an important factor in keeping GLP-1 studies on track.
The GLP-1 landscape is getting more complex
The success of the first generation of GLP-1 therapies has accelerated investment and innovation across the metabolic disease landscape.
Development is expanding beyond traditional GLP-1 receptor agonists to include dual and triple agonists, new combinations, alternative delivery methods and therapies targeting a wider range of metabolic conditions.
The indications being explored are expanding too.
Obesity and type 2 diabetes remain central to the category, but GLP-1-based therapies are increasingly being investigated across interconnected conditions including cardiovascular disease, chronic kidney disease, obstructive sleep apnea and metabolic liver disease.
This creates a more competitive clinical research environment in which multiple studies may be targeting overlapping patient populations.
For sponsors, identifying eligible patients is therefore only part of the challenge. Studies also need to make participation manageable enough for patients to remain engaged throughout the protocol.
A large patient population does not mean a low recruitment burden
The prevalence of obesity and metabolic disease means the theoretical patient population for many GLP-1 studies can be substantial.
In practice, however, the number of patients who are eligible, willing and realistically able to participate can be considerably smaller.
Protocol inclusion and exclusion criteria, comorbidities, previous or current treatment, geographic access to research sites and the time commitment required from patients can all narrow the available population.
Competition between clinical trials and increasing access to approved GLP-1 therapies can add another consideration: why should a patient participate in a clinical study when alternative treatment options may already be available?
This makes the experience surrounding the investigational treatment increasingly important.
Reducing unnecessary logistical and financial barriers can broaden access to studies and help make participation a realistic option for patients who might otherwise be unable or unwilling to take part.
GLP-1 studies can demand long-term commitment from patients
Enrolling a patient is only the beginning.
Depending on the protocol and indication, metabolic clinical trials can involve regular site visits, laboratory testing, physical assessments, treatment administration, dose escalation, lifestyle interventions and extended follow-up.
Some studies are particularly long. The Phase 3 trial supporting the US approval of semaglutide in MASH, for example, includes a planned total study duration of 240 weeks to assess longer-term clinical outcomes.
The burden of participation can therefore accumulate.
A single site visit may appear manageable on paper. Across months or years of participation, however, repeated travel, time away from work, childcare requirements and out-of-pocket expenses can become significant barriers.
Patients may also be managing obesity alongside diabetes, cardiovascular disease, liver disease or other comorbidities, making frequent travel and rigid study schedules more difficult.
Designing support around these realities can make it easier for patients to continue participating throughout the study.
Retention is about more than keeping patients enrolled
Strong patient retention has implications beyond enrollment numbers.
When patients miss visits or leave a study early, sponsors can face missing data, additional site workload, replacement recruitment and potential delays to study milestones.
This makes retention a study performance issue as much as a patient experience issue.
Clinical trials of GLP-1 therapies have demonstrated that high levels of treatment adherence can be achieved within the structured environment of a clinical study. Published Phase 3 data for subcutaneous semaglutide and tirzepatide have reported more than 80% of patients completing trials while remaining on study treatment.
Creating an environment that supports patients throughout their participation can help protect that engagement.
That means looking beyond the treatment itself and considering the complete patient journey.
Reducing the practical burden of participation
Patient support can remove many of the practical barriers that have little to do with the investigational therapy but can have a significant impact on the patient’s ability to remain in a study.
For GLP-1 and metabolic disorder studies, this can include arranging travel and accommodation for site visits, managing patient payments and reimbursements, coordinating appointments and providing a consistent point of contact throughout participation.
Where the protocol allows, decentralized clinical services can bring certain study activities directly to the patient’s home.
Home-based visits can reduce the number of journeys patients need to make to research sites while still supporting protocol requirements. For patients taking part over extended periods, reducing even a proportion of site visits can make participation significantly easier to manage alongside everyday life.
Importantly, these services should not operate in isolation.
A connected support model allows travel, payments, decentralized services and patient coordination to work around the same patient journey, reducing complexity for patients, sites and study teams.
Building scalable patient support into GLP-1 studies
As GLP-1 development programs grow in size and geographic reach, patient support also needs to scale.
mdgroup provides global patient support for metabolic disorder clinical trials through a connected range of services, including:
- Patient travel, accommodation and relocation
- Patient payments, stipends and reimbursements
- Decentralized clinical services and in-home visits
- Personalized patient coordination
- Clinical staffing
- Clinical logistics
By bringing these services together through one global partner, sponsors can build support around the requirements of individual protocols and patient populations without creating additional complexity through multiple vendors.
The objective is simple: remove avoidable barriers between patients and successful study participation.
Supporting the next generation of metabolic clinical trials
The GLP-1 landscape is continuing to evolve rapidly.
As development expands across obesity, diabetes, MASH and other metabolic conditions, competition and complexity are likely to increase alongside it.
The sponsors that consider patient support early in study planning can create protocols that are not only scientifically robust, but more practical for patients to participate in over the long term.
Because making clinical trials easier for patients to stay in can contribute to outcomes that matter across the entire study:
Higher retention. Better data. Faster trials.
Planning a GLP-1 or metabolic disorder study?
Talk to our team about how mdgroup can help reduce patient burden and support retention throughout your clinical trial.
